Cannabinoid receptor type I modulates alcohol-induced liver fibrosis

Molecular Medicine

Volumn 17, Issue 11, 2011, Pages 1285-1294

  Patsenker, Eleonora ^a   Stoll, Matthias ^b,d   Millonig, Gunda ^c   Agaimy, Abbas ^b   Wissniowski, Till ^b   Schneider, Vreni ^a   Mueller, Sebastian ^c   Brenneisen, Rudolf ^a   Seitz, Helmut K ^c   Ocker, Matthias ^b,d   Stickel, Felix ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ACETALDEHYDE; ALCOHOL; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; HYDROGEN PEROXIDE; MESSENGER RNA; RIMONABANT; TETRAHYDROCANNABINOLIC ACID;

ADULT; ALCOHOL LIVER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE ACTIVITY; DOWN REGULATION; DRUG MEGADOSE; FEMALE; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER BIOPSY; LIVER FIBROSIS; MALE; MMP13 GENE; MOUSE; NONHUMAN; PCALPHA1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; RECEPTOR BLOCKING; REGULATORY MECHANISM; STELLATE CELL; TIMP1 GENE; UPREGULATION;

ACETALDEHYDE; ANIMALS; APOPTOSIS; CANNABINOIDS; CELL HYPOXIA; CELL PROLIFERATION; COLLAGEN; FEMALE; HEPATIC STELLATE CELLS; HUMANS; HYDROGEN PEROXIDE; INFLAMMATION; LIVER; LIVER CIRRHOSIS, ALCOHOLIC; MALE; MATRIX METALLOPROTEINASES; MICE; MIDDLE AGED; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RNA, MESSENGER; UP-REGULATION;

EID: 82855164046     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00149     Document Type: Article

References (48)

1. Bataller R, Brenner DA. (2005) Liver fibrosis. J. Clin. Invest. 115:209-18.
2. Bataller R, Brenner DA. (2001) Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin. Liver Dis. 21:437-51.
3. Parsons CJ, Takashima M, Rippe RA. (2007) Molecular mechanisms of hepatic fibrogenesis. J. Gastroenterol. Hepatol. 22 Suppl 1:S79-84.
4. Friedman SL. (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology. 134:1655-69.
5. Mallat A, Teixeira-Clerc F, Deveaux V, Lotersztajn S. (2007) Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases. Expert Opin. Ther. Targets 11:403-9.
6. Caraceni P, Domenicali M, Bernardi M. (2008) The endocannabinoid system and liver diseases. J. Neuroendocrinol. 20 Suppl 1:47-52.
7. Parfieniuk A, Flisiak R. (2008) Role of cannabinoids in chronic liver diseases. World J. Gastroenterol. 14:6109-14.
8. Siegmund SV, Schwabe RF. (2008) Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 294:G357-62.
9. Teixeira-Clerc F, et al. (2006) CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat. Med. 12:671-6.
10. Julien B, et al. (2005) Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology. 128:742-55.
11. Ishida JH, et al. (2008) Influence of cannabis use on severity of hepatitis C disease. Clin. Gastroenterol. Hepatol. 6:69-75.
12. Hezode C, et al. (2005) Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology. 42:63-71.
13. Hezode C, et al. (2008) Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology. 134:432-9.
14. Caraceni P, et al. (2009) Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver Int. 30:816-25.
15. Biswas KK, et al. (2003) Membrane cholesterol but not putative receptors mediates anandamideinduced hepatocyte apoptosis. Hepatology. 38:1167-77.
16. Osei-Hyiaman D, et al. (2005) Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 115:1298-305.
17. Siegmund SV, et al. (2006) Fatty acid amide hydrolase determines anandamide-induced cell death in the liver. J. Biol. Chem. 281:10431-8.
18. Maccarrone M, Finazzi-Agro A. (2003) The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis. Cell Death Differ. 10:946-55.
19. Siegmund SV, Uchinami H, Osawa Y, Brenner DA, Schwabe RF. (2005) Anandamide induces necrosis in primary hepatic stellate cells. Hepatology. 41:1085-95.
20. Siegmund SV, et al. (2007) The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. FASEB J. 21:2798-806.
21. Jeong WI, et al. (2008) Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab. 7:227-35.
22. Trebicka J, et al. (2011) Role of cannabinoid receptors in alcoholic hepatic injury: steatosis and fibrogenesis are increased in CB2 receptor-deficient mice and decreased in CB1 receptor knockouts. Liver Int. 31:860-70.
23. Louvet A, et al. (2011) Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating kupffer cell polarization in mice. Hepatology. doi: 10.1002/hep.24524. [Epub ahead of print].
24. Siegmund SV, Haas S, Singer MV (2005) Animal models and their results in gastrointestinal alcohol research. Dig. Dis. 23:181-94.
25. Kleiner DE, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41:1313-21.
26. Kornek M, et al. (2006) Combination of systemic thioacetamide (TAA) injections and ethanol feeding accelerates hepatic fibrosis in C3H/He mice and is associated with intrahepatic up regulation of MMP-2, VEGF and ICAM-1. J. Hepatol. 45:370-6.
27. Patsenker E, et al. (2008) Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology. 135:660-70.
28. Patsenker E, et al. (2009) Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology. 50:1501-11.
29. Patsenker E, Popov Y, Wiesner M, Goodman SL, Schuppan D. (2007) Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BBinduced hepatic stellate cell migration and activation in vitro. J. Hepatol. 46:878-87.
30. Failli P, et al. (1995) The mitogenic effect of platelet-derived growth factor in human hepatic stellate cells requires calcium influx. Am. J. Physiol. 269: C1133-9.
31. Inagaki Y, et al. (1995) Regulation of the alpha 2(I) collagen gene transcription in fat-storing cells derived from a cirrhotic liver. Hepatology. 22:573-9.
32. Rojkind M, et al. (1995) Characterization and functional studies on rat liver fat-storing cell line and freshly isolated hepatocyte coculture system. Am. J. Pathol. 146:1508-20.
33. Pacher P, Gao B. (2008) Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases. Am. J. Physiol. Gastrointest. Liver Physiol. 294:G850-4.
34. Benyon RC, Arthur MJ. (2001) Extracellular matrix degradation and the role of hepatic stellate cells. Semin. Liver Dis. 21:373-84.
35. Fallowfield JA, et al. (2007) Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J. Immunol. 178:5288-95.
36. Winwood PJ, et al. (1995) Kupffer cell-derived 95- kd type IV collagenase/gelatinase B: characterization and expression in cultured cells. Hepatology. 22:304-15.
37. Popov Y, et al. Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 298:G323-34.
38. Olaso E, et al. (2001) DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells. J. Clin. Invest. 108:1369-78.
39. Popov Y, Patsenker E, Fickert P, Trauner M, Schuppan D. (2005) Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J. Hepatol. 43:1045-54.
40. Klein TW, et al. (2003) The cannabinoid system and immune modulation. J. Leukoc. Biol. 74:486-96.
41. Gary-Bobo M, et al. (2007) Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology. 46:122-9.
42. Chen YH, Wang MF, Liao JW, Chang SP, Hu ML. (2008) Beneficial effects of nicotinamide on alcoholinduced liver injury in senescence-accelerated mice. Biofactors. 34:97-107.
43. Brenner DA, Chojkier M. (1987) Acetaldehyde increases collagen gene transcription in cultured human fibroblasts. J. Biol. Chem. 262:17690-5.
44. Eriksson CJ, Sippel HW. (1977) The distribution and metabolism of acetaldehyde in rats during ethanol oxidation-I. The distribution of acetaldehyde in liver, brain, blood and breath. Biochem. Pharmacol. 26:241-7.
45. Chen A. (2002) Acetaldehyde stimulates the activation of latent transforming growth factor-beta1 and induces expression of the type II receptor of the cytokine in rat cultured hepatic stellate cells. Biochem. J. 368:683-93.
46. Siegmund SV, Dooley S, Brenner DA. (2005) Molecular mechanisms of alcohol-induced hepatic fibrosis. Dig. Dis. 23:264-74.
47. Soyka M, et al. (2008) Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebocontrolled, double-blind trial. J. Clin. Psychopharmacol. 28:317-24.
48. European Medicines Agency. (2008) The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia [press release]. [cited 2011 Oct 28]. Available from: http://www.ema.europa.eu/ema/ index.jsp?curl= pages/news_and_events/news/ 2009/11/news_detail_000244.jsp&murl=menus/news_and_events/ news_and_events.jsp&mid=WC0b01ac058004d5c1&jsenabled=true